Shieh Eugenie C, Weld Ethel D, Fuchs Edward J, Hiruy Hiwot, Buckheit Karen W, Buckheit Robert W, Breakey Jennifer, Hendrix Craig W
1 Department of Medicine, Johns Hopkins School of Medicine , Baltimore, Maryland.
2 ImQuest BioSciences , Frederick, Maryland.
AIDS Res Hum Retroviruses. 2017 Aug;33(8):784-787. doi: 10.1089/AID.2016.0318. Epub 2017 Jul 24.
Given the rising HIV incidence in men who have sex with men (MSM) despite repeatedly proven effectiveness of oral HIV pre-exposure prophylaxis, behaviorally congruent periodic dosing strategies, such as dosing microbicides as lubricants, are now in demand. Rectal microbicide gel studies largely administer gels using vaginal applicators, which have not been well received and do not mimic lubricant use. We compared rectal gel manually dosed as lubricant with applicator dosing in five healthy, HIV-negative MSM who received 10 or 3.5 ml of Tc-DTPA-radiolabeled hydroxyethyl cellulose universal placebo gel intrarectally. After washout, participants received 10 ml of radiolabeled Wet Original lubricant to apply to the anus with fingers and/or a phallus in a manner typical of sexual lubricant use with a partner, followed by simulated receptive anal intercourse. Single-photon emission computed tomography with transmission computed tomography was performed 4 h after each gel administration. Manual dosing was associated with more variable rectosigmoid distribution, 4.4-15.3 cm from the anorectal junction, compared with more uniform distribution, 5.9-7.4 and 5.3-7.6 cm after 10 and 3.5 ml applicator dosing, respectively. A significantly smaller fraction of the initial 10 ml dose was retained within the colon after manual dosing, 3.4%, compared with 94.9% and 88.4% after 10 and 3.5 ml applicator dosing, respectively (both p < .001). Manual dosing of a sexual lubricant delivered a small, variable fraction of the dose with variable rectosigmoid distribution compared with applicator dosing. These results raise concern that dosing a rectal microbicide gel as a sexual lubricant may not provide adequate or predictable mucosal coverage for HIV protection.
尽管口服HIV暴露前预防措施已被反复证明有效,但男男性行为者(MSM)中的HIV发病率仍在上升,因此现在需要行为上一致的定期给药策略,例如将杀微生物剂作为润滑剂给药。直肠杀微生物剂凝胶研究大多使用阴道给药器给药,这种给药器不受欢迎,也无法模拟润滑剂的使用方式。我们比较了在5名健康的HIV阴性MSM中,将直肠凝胶作为润滑剂手动给药与使用给药器给药的情况,这些参与者接受了10毫升或3.5毫升经锝-二乙三胺五乙酸(Tc-DTPA)放射性标记的羟乙基纤维素通用安慰剂凝胶直肠给药。洗脱期过后,参与者接受10毫升放射性标记的Wet Original润滑剂,用手指和/或阴茎以与伴侣进行性润滑时的典型方式涂抹于肛门,随后进行模拟接受式肛交。每次凝胶给药4小时后进行单光子发射计算机断层扫描并结合透射计算机断层扫描。与使用给药器分别给予10毫升和3.5毫升凝胶后直肠乙状结肠分布更均匀(分别为距肛门直肠交界处5.9 - 7.4厘米和5.3 - 7.6厘米)相比,手动给药时直肠乙状结肠分布更不均匀,距肛门直肠交界处4.4 - 15.3厘米。手动给药后,最初10毫升剂量中留在结肠内的部分显著更少,为3.4%,而使用给药器分别给予10毫升和3.5毫升凝胶后,这一比例分别为94.9%和88.4%(两者p均<0.001)。与使用给药器给药相比,手动给予性润滑剂时,剂量的一小部分分布可变,直肠乙状结肠分布也不均匀。这些结果令人担忧,将直肠杀微生物剂凝胶作为性润滑剂给药可能无法为预防HIV提供足够或可预测的黏膜覆盖。